InspireMD (NSPR)
Develops CGuard mesh-covered carotid stents for stroke prevention.
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025.
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of August 3, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of June 12, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year.
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio.
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13th at 4:20 pm Pacific Time (PT). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com.
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD Reports First Quarter 2026 Financial Results
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in TCAR procedures - - FDA approval of the original CGuard delivery system anticipated in Q3 2026 - - On track for expected FDA approval of the CGuard Prime 80 cm for TCAR procedures in H2 2026, potentially doubling the Company's addressable market - MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2026. Recent Business Highlights: Generated revenue of $3.4 million in the first quarter of 2026, up 122% year-over-year, with significant growth in demand for CGuard Prime in the U.S. and original CGuard in international markets.
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% -
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the company's Investigational Device Exemption (“IDE”) Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), including next generation enhancements from our prior IDE approval for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures.
InspireMD to Announce First Quarter 2026 Financial Results
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.
InspireMD to Announce First Quarter 2026 Financial Results
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)
NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating InspireMD, Inc. (NASDAQ: NSPR) on behalf of the company's shareholders. The investigation seeks to determine whether InspireMD's directors breached their fiduciary duties in connection with recent corporate actions.
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.